Quisinostat HCl (formerly JNJ-26481585; JNJ 26481585; JNJ26481585), the hydrochloride salt of Quisinostat, is an orally bioavailable, 2nd generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antitumor activity.

NKL 22 formerly known as HDAC inhibitor IV with CAS#537034-15-4, is a HDAC inhibitor.

HDAC-IN-7 is a Chidamide impurity. Chidamide is an anticancer drug that acts as a potent and orally bioavailable inhibitor of HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10).

SR-4370 is an inhibitor of HDAC (Histone deacetylases), with IC50 values of 0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC6, respectively.

BML-210 (also known as BML210; CAY-10433) is novel and potent HDAC inhibitor (IC50 value: 5 μM) with anticancer activity.

NR-160 is a novel, potent and selective HDAC6 (Histone Deacetylase 6) inhibitors with bifurcatedcapping groups.

Tubastatin A (TubA, AG-CR13900) TFA, the trifluoroacetic acid salt of TubA, is an inhibitor of HDAC6 with anticancer and anti-inflammatory activity.

SS-208 is a novel, potent and selective HDAC6 inhibitor, with an IC50 of 12 nM and with anti-tumor activity.

ITSA-1 is a novel, potent, cell-membrane permeable and specific HDAC (Histone deacetylase) inhibitor that suppresses TSA inhibition of HDAC (histone deacetylase), but not other HDAC inhibitors.

Sodium Butyrate, the sodium salt of butyrate, is an histone deacetylase (HDAC) inhibitor with anticancer activity.